Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Physiologic Insulin Delivery in T1D
NCT04416737Phase 1Completed
- Sponsor
- Stanford University
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human insulin in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Stanford University. Primary endpoint: Glucagon Response to Induced Hypoglycemia. Started Nov 2021; status: completed.
02
Drugs
human insulin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04416737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416737.